Introduction
============

Renal cell carcinoma (RCC) is the most common type of cancer arising from the kidney, and its incidence is steadily rising by about 2% per year.[@b1-ott-8-313] RCC is more common in males than in females (ratio 2:1), and most often occurs in patients aged 50--70 years. A total of 66,466 new cases of kidney tumors were diagnosed in the People's Republic of China in 2012, which represents almost twice the number diagnosed in the USA. However, the incidence of kidney tumors in the People's Republic of China is still lower than the global incidence rate on average. This difference may result from environmental exposure and genetic predisposition. Further, the incidence of kidney tumors in males was listed as the seventh most common type of cancer in the People's Republic of China in 2012.[@b2-ott-8-313] Surgery is the mainstay of curative treatment if the patient can be diagnosed early. Compared with liver cancer and other aggressive cancers, RCC usually has a good prognosis following curative surgery. Up to 30% of RCC patients present with metastatic disease and have a median survival of 7--11 months.

RCC is resistant to chemotherapy and radiotherapy. Approximately 20% of patients with advanced RCC respond efficiently to interleukin-2-based immunotherapy. Targeted therapies are the major systematic approach for advanced or metastatic RCC in Western countries. Currently, there are two kinds of therapeutic agents applied in targeted therapy for RCC, ie, tyrosine kinase inhibitors (TKIs) targeting tumor angiogenesis and mammalian target of rapamycin (mTOR) inhibitors. Sorafenib is the first approved TKI that has been recommended as first-line or second-line treatment for stage IV RCC, recurrent RCC, and metastatic RCC by the US Food and Drug Administration (FDA) since 2005.[@b3-ott-8-313] Thereafter, several TKIs, mainly targeting the vascular endothelial growth factor (VEGF) receptor or platelet-derived growth factor receptor, including sunitinib, pazopanib, and axitinib, as well as the anti-VEGF monoclonal antibody, bevacizumab, have been applied to targeted therapy for this malignancy worldwide. Everolimus, which is designed to target mTOR pathways, has also been approved as second-line treatment after TKI treatment failure and has had great clinical benefit for patients who are refractory to first-line targeted therapy. Temsirolimus, also targeting mTOR pathways, has been recommended as a category 1 agent for first-line treatment of RCC patients of poor prognosis, predominantly for unresectable clear cell stage IV or non-clear cell RCC.

However, the situation regarding targeted therapy, in particular everolimus, for advanced or metastatic RCC in the People's Republic of China remains largely unknown. RCC is a highly heterogeneous tumor and the effect of targeted therapy may differ between races,[@b4-ott-8-313],[@b5-ott-8-313] so it is necessary to summarize the progress made regarding targeted therapy in the People's Republic of China and provide evidence for standardizing the procedure for treating advanced RCC. Although many international clinical trials of targeted agents including sorafenib, sunitinib, everolimus, axitinib, temsirolimus, and pazopanib have been registered or performed in Mainland China, only three therapeutic agents are approved by the Chinese FDA for the treatment of advanced RCC, ie, two TKIs (sorafenib and sunitinib) and one mTOR inhibitor (everolimus). Further, according to related English publications on PubMed and major scientific publications in Chinese, outcomes of clinical trials for agents not approved in the People's Republic of China have not been reported independently. Although the clinical studies of the agents approved in Mainland China are relatively less extensive compared with those in Western countries, the primary results obtained so far are important in terms of improving the targeted therapies for this malignancy in the People's Republic of China.

Sorafenib
=========

Sorafenib, the most popular multitargeting TKI, was approved as a first-line and second-line therapeutic agent for advanced RCC by the Chinese FDA in November 2006. The clinical benefit rate (complete response, partial response, and stable disease) in Chinese RCC patients in four studies[@b6-ott-8-313]--[@b9-ott-8-313] published in international journals ranged from 80.0% to 88.1%, which was similar to that in the TARGET (Treatment Approach in Renal Cancer Global Evaluation Trial),[@b3-ott-8-313] EU-ARCCS (European Renal Cell Carcinoma Sorafenib program),[@b10-ott-8-313] and NA-ARCCS (North America Renal Cell Carcinoma Sorafenib program) trials.[@b11-ott-8-313] Further, the objective response (complete response and partial response) was much higher in Chinese patients (21%--36.6%) than in Western populations (4%--10.2%). This favorable outcome also included prolonged progression-free survival (PFS), with medians ranging from 9.6 weeks to 15 weeks. A similar trend has been observed in Japanese and Korean patients.[@b12-ott-8-313],[@b13-ott-8-313] Hand-foot syndrome, diarrhea, fatigue, loss of appetite, and alopecia are the most common adverse effects of sorafenib in Chinese patients, and are usually manageable. Further, compared with Western patients, Chinese patients with RCC tend to derive more clinical benefit and have fewer adverse effects with an increasing dosage of sorafenib. The clinical benefit rate can reach 80% or more with dose escalation of sorafenib to 1,200 mg or 1,600 mg daily or 600 mg twice a day in patients who have experienced failure on sorafenib at a conventional dosage.[@b14-ott-8-313] However, dose escalation of sorafenib might have a negative impact on tolerance. The optimal maximum tolerated dosage to gain more clinical benefit without a significant increase in adverse effects needs to be verified in long-term clinical studies with large sample sizes. Thus, sorafenib can be more effective in Chinese patients than in Western patients and well tolerated if high dosages are administered.[@b15-ott-8-313]

Sunitinib
=========

Sunitinib is another multitargeting TKI, and was approved by the Chinese FDA in May 2008. Sunitinib is a gold standard first-line treatment for advanced RCC internationally.[@b16-ott-8-313] The efficacy and toxicity of sunitinib have rarely been reported in Chinese patients with RCC. In 2012, Ye et al[@b17-ott-8-313] reported a prospective, multicenter, single-arm, Phase IV clinical trial of standard application of sunitinib in patients with advanced RCC in Mainland China. Of 105 patients enrolled, the disease control rate was 76.9%, the objective response was 31.1%, and the median PFS was 13.5 months. The objective response rate and median PFS were 31% and 11 months, respectively, in Western patients.[@b18-ott-8-313],[@b19-ott-8-313] More recently, He et al[@b20-ott-8-313] reported a study of 141 patients with metastatic RCC, including 119 patients who received single-agent sunitinib as first-line therapy and 22 patients who received it as second-line therapy at two Chinese centers. The clinical benefit rate was 87.2%, the objective response rate was 26.9%, and median PFS was 14.2 months. The two Chinese studies reported a longer PFS than that in Western patients. However, the objective response rate did not show an obvious increase. Further, 36.9% of the patients needed dose reduction or treatment interruption because of adverse effects.[@b20-ott-8-313] The most common adverse effects were thrombocytopenia, hypothyroidism, neutropenia, hand-foot syndrome, and hypertension. Yoo et al[@b21-ott-8-313] also reported that Korean RCC patients receiving sunitinib therapy had a higher incidence of adverse events than Western patients, with 46% requiring dose reduction. Genetic polymorphism in the ABCG2 gene (421C\>A) may contribute to sunitinib-related toxicity in Korean patients with metastatic RCC.[@b22-ott-8-313] Toxicity profiles related to racial differences need to be investigated further. Careful follow-up is necessary to ensure continuation of sunitinib therapy.[@b23-ott-8-313] Thus, sunitinib has a therapeutic effect comparable with that of sorafenib, but has a more severe toxicity profile in Asian patients than in Western patients. The toxicities of sunitinib in Asians might be determined by genetic predisposition.

Everolimus
==========

Despite the tremendous improvements in targeted therapies for metastatic RCC, it has been reported that most patients develop resistance to anti-VEGF therapy after 6 months to 3 years of disease control, and eventually die after disease relapse.[@b24-ott-8-313] It has been demonstrated that the phosphatidylinositol-4 5-bisphosphate 3-kinase (PI3K)/AKT/mTOR pathway plays an important role in renal carcinogenesis and disease progression,[@b25-ott-8-313],[@b26-ott-8-313] and mTOR is the key downstream molecule of the PI3K/AKT pathway. Activation of mTOR promotes proliferation and survival of tumor cells and metabolism. It is also involved in proangiogenic signaling pathways in endothelial cells. Thus, mTOR can be taken as a central target for targeted RCC therapy. Everolimus, a specific mTOR inhibitor that can be orally administered, was approved for patients with advanced RCC refractory or intolerant to TKI therapy by the Chinese FDA in January 2013. This might facilitate the improvement of targeted therapy for advanced RCC. However, clinical evaluation of the efficacy and toxicity of everolimus in Chinese RCC patients is quite limited and preliminary. Most of the clinical studies are just registered and ongoing.

Efficacy
--------

Guo et al[@b27-ott-8-313] conducted an open-label, multicenter, Phase Ib clinical trial in metastatic RCC (clinical trials.gov identifier NCT01152801). As shown in [Table 1](#t1-ott-8-313){ref-type="table"}, of 64 patients with metastatic RCC either intolerant to previous VEGF receptor-TKI therapy or progressed after therapy, three patients had a partial response, 39 patients had stable disease after treatment with everolimus, and no patient had a complete response. In that study, the median PFS was 6.9 months, which was much longer than the data obtained from the multicenter, randomized, double-blind, placebo-controlled, Phase III trial known as RECORD-1 (Renal Cell cancer treatment with Oral RAD001 given Daily).[@b28-ott-8-313],[@b29-ott-8-313] In addition, Huang et al[@b30-ott-8-313] retrospectively observed the therapeutic effect of everolimus in 24 patients with metastatic RCC who had previously received sorafenib or sunitinib or both treatments in Taiwan. None of these patients had a complete or partial response. However, 62.5% had stable disease and the median PFS was 7.1 months. The PFS was similar to that in Guo's study.[@b27-ott-8-313] Kato et al[@b31-ott-8-313] reviewed 19 Japanese patients with metastatic RCC and found a similar PFS. However, Park et al[@b32-ott-8-313] reviewed 100 Korean patients with metastatic RCC who received everolimus as second-line treatment and found that the median PFS was 4.2 months, which is consistent with the PFS in RECORD-1[@b28-ott-8-313] and RECORD-1 (updated).[@b29-ott-8-313] The inconsistency in the therapeutic effect of everolimus in the four Asian studies might be explained by two factors. First, the sample size was small, and the population sample size needs to be larger to verify if everolimus as second-line targeted therapy is suitable for Asian patients with metastatic RCC. Second, the RCC histology was not consistent. Histology type is an important predictor of therapeutic response to everolimus, because everolimus favors the clear cell type over other types. All tumor histology was of the clear cell type in the study by Guo et al and in the RECORD-1 trial, whereas non-clear cell types were also enrolled in other studies ([Table 1](#t1-ott-8-313){ref-type="table"}). In addition, clinical risk categories might affect the clinical response. The patients in the study by Guo et al and those in RECORD-1 had a Karnofsky performance status of at least 70%; however, the risk categories were not presented in the study by Guo et al. Nevertheless, Asian patients might respond better than or similar to Western patients.

Another open-label, multicenter, randomized, Phase I clinical study carried out in Chinese patients with advanced breast cancer, gastric cancer, non-small cell lung cancer, or RCC has demonstrated that everolimus at a dose of 5 mg or 10 mg per day is well tolerated in Chinese patients, and the most common adverse effects are mild to moderate in intensity.[@b33-ott-8-313] These two dose levels of everolimus share a similar adverse effect profile, except that more patients in the 10 mg/day group suffered adverse effects than those in the 5 mg/day group. These adverse effects include hyperglycemia, fatigue, and anemia, and are manageable with careful monitoring. This study indicates that everolimus may benefit patients with RCC more than those with other types of cancer, because RCC patients can stand for the longest median duration of everolimus treatment of 184.5 days among the patients with cancer of these histotypes.

Safety
------

Rates of discontinuation due to side effects range from 3.7% to 23.0% in the studies of everolimus ([Table 1](#t1-ott-8-313){ref-type="table"}). In addition, approximately one third of patients need drug interruption or dose reduction due to adverse effects. However, judicious dose reductions may prolong the duration of everolimus treatment, thus contributing to prolonged overall survival in Asian and non-Asian patients.[@b34-ott-8-313] Guo et al[@b27-ott-8-313] documented that 42% of RCC patients reported more than one adverse effect related to treatment with everolimus. As shown in [Table 2](#t2-ott-8-313){ref-type="table"}, the most common adverse effects were anemia, mouth ulceration, pyrexia, fatigue, rash, hypertriglyceridemia, hypercholes-terolemia, hyperglycemia, and noninfectious pneumonitis, ie, a toxicity profile similar to that seen in Western patients. Among these adverse effects, mouth ulceration, pyrexia, rash, and noninfectious pneumonitis occurred more often in Chinese patients than in Western patients, whereas metabolic abnormalities, including anemia, hypertriglyceridemia, and hypercholesterolemia, occurred more often in Western patients than in Chinese patients.[@b28-ott-8-313],[@b29-ott-8-313] Such a trend was also seen in another group of Chinese patients in Taiwan,[@b30-ott-8-313] indicating that differences in genetic background may contribute to the difference in everolimus-related metabolism seen between Chinese and Western patients. Pneumonitis is a toxicity associated with rapamycin and rapamycin analogs, and Chinese patients have high rates of pneumonitis of all grades or pneumonitis of grades 3/4 ([Table 2](#t2-ott-8-313){ref-type="table"}). Kato et al[@b31-ott-8-313] also found that Japanese patients suffered more severe pneumonitis. Specifically, anemia occurred more in Chinese patients of grades 3/4 than in Western patients of the same grades though it was less in Chinese patients with adverse effects of all grades, which reminds Chinese health care providers to pay more attention to the special adverse effects due to cumulative toxicity of TKIs[@b35-ott-8-313] and minimize the risk of deterioration.

Although everolimus rarely results in a complete response, it can stabilize the disease as well as prolong PFS and overall survival. Everolimus has advantages when compared with temsirolimus and sorafenib[@b36-ott-8-313] as second-line targeted treatments in RCC patients, regardless of the initial targeted therapy used. Because of its comparable safety and ability to be administered orally, everolimus could improve quality of life for Chinese RCC patients who are resistant to first-line TKIs.

Sequential targeted therapy
===========================

Although several targeted agents are proven to be effective in improving the treatment of patients with advanced RCC, most patients eventually develop drug resistance and disease progression. Thus, sequential targeted therapy may yield more clinical benefit via a tailored therapy design. Motzer et al[@b37-ott-8-313] performed a large, randomized, multicenter Phase II trial (RECORD-3) that compared sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic RCC using a crossover treatment design. Compared with sunitinib alone, treatment with everolimus resulted in a shorter median PFS (7.9 months versus 10.7 months, hazard ratio 1.4, 95% confidence interval 1.2--1.8). Compared with the everolimus-sunitinib paradigm, the sunitinib-everolimus paradigm might contribute to longer median PFS (25.8 months versus 21.1 months, hazard ratio 1.3, 95% confidence interval 0.9--1.7) and overall survival (32.0 months versus 22.4 months, hazard ratio 1.2, 95% confidence interval 0.9--1.6), although this contribution did not reach a statistically significant level. The sunitinib-everolimus paradigm is still recommended as standard therapy. Li et al[@b38-ott-8-313] undertook sequential targeted therapy in Chinese patients with metastatic RCC in Taiwan and reported that second-line everolimus achieved a fair degree of disease control in patients whose first-line sunitinib treatment resulted in primary resistance. However, the therapeutic efficacy of sequential targeted therapy using everolimus is rarely confirmed in Chinese patients. Thus, the role of everolimus in sequential targeted therapy for Chinese patients needs to be explored in more depth and verified by clinical studies with a large sample size and rigorous design.

Prediction of efficacy of everolimus
====================================

The therapeutic efficacy of everolimus depends on the unique and indispensible role of the PI3K/AKT/mTOR pathway in the progression of metastatic RCC. The efficacy can be greatly reduced by feedback loops, given that the PI3K/AKT/mTOR pathway has crosstalk with other important signaling pathways, including the CXCR4-CXCL12-CXCR7 chemokine receptor axis, the nuclear factor κB pathway, and the hedgehog pathway.[@b39-ott-8-313]--[@b41-ott-8-313] Thus, clarification of the role of the PI3K/AKT/mTOR-centered signaling network and the mutation pattern of hub genes[@b42-ott-8-313] in this network in renal carcinogenesis and progression, will be helpful in designing everolimus-based sequential targeted therapy. Recently, Santoni et al[@b43-ott-8-313] systematically summarized the major pathways that have crosstalk with the PI3K/AKT/mTOR pathway and the sites of mutation in the PI3K/AKT/mTOR network, including PI3K, PTEN, and phosphorylated 4E-binding protein 1 that could result in resistance to everolimus therapy. The effect of these pathways and somatic mutations on resistance to everolimus therapy should be systematically evaluated in the Chinese population. Understanding the mechanisms by which metastatic RCC cells develop resistance to mTOR inhibitors may lead to identification of more efficient and specific ways to overcome resistance to everolimus and facilitate prognostication in patients with advanced RCC.

Using immunohistochemistry, a study by Li et al[@b44-ott-8-313] (clinical trials.gov identifier NCT01152801) found that positive expression of phosphorylated mTOR in paraffin-embedded tumor tissue specimens from Chinese patients with TKI-refractory metastatic RCC was significantly associated with a better clinical benefit rate and longer PFS on everolimus and that positive expression of phosphorylated 40S ribosomal protein S6 was significantly associated with a longer PFS on everolimus. The expression level of phosphorylated 4E-binding protein 1 was shown to be an independent predictor of the response to treatment with mTOR inhibitors in Japanese patients with metastatic RCC.[@b45-ott-8-313] The pretreatment neutrophil-to-lymphocyte ratio in peripheral blood has been shown to be an independent prognostic factor for patients with metastatic RCC who received everolimus as second-line or third-line treatment.[@b46-ott-8-313] When the neutrophil-to-lymphocyte ratio was less than 3, the median PFS and OS in this study was 9.9 months and 24.4 months, ie, longer than the corresponding results in the RECORD-1 trial. As the activation profile of the signal network has better specificity and sensitivity than individual genes in predicting the prognosis of cancer patients,[@b47-ott-8-313] the presence of the above-mentioned molecules or cells in clinical samples from increasing clinical trials of everolimus can be used to develop a prognostic system to improve the outlook for patients with metastatic RCC, thus guiding clinical decision-making.

Conclusion
==========

In summary, we have outlined the recent progress in use of targeted therapies for advanced RCC in the People's Republic of China ([Table 3](#t3-ott-8-313){ref-type="table"}), in particular treatment using everolimus. Compared with Western patients, Chinese patients with advanced or metastatic RCC respond better to sorafenib and sunitinib as first-line targeted therapy, but sunitinib has a relatively higher rate of toxicity. Everolimus, an mTOR inhibitor that can be orally administered, is well tolerated and acceptable for Chinese patients. Everolimus has competitive advantages as second-line targeted treatment for Chinese patients with advanced or metastatic RCC who are resistant to first-line TKIs. Although most studies of targeted therapies for advanced RCC have obvious limitations, such as small sample size and retrospective design, the evidence so far indicates that everolimus should be effective as second-line targeted therapy for advanced RCC in the People's Republic of China.
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###### 

Efficacy of everolimus applied as second-line treatment in Chinese patients with advanced renal cell carcinoma, as compared with Western patients[a](#tfn1-ott-8-313){ref-type="table-fn"}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Design                                                                                  Sample size        Histology type (%)      Previous target therapy (n)        Median duration of everolimus exposure   Discontinuation[b](#tfn2-ott-8-313){ref-type="table-fn"} n (%)   Efficacy of everolimus                          
  ------------------------------------ --------------------------------------------------------------------------------------- ------------------ ----------------------- ---------------------------------- ---------------------------------------- ---------------------------------------------------------------- ------------------------ --------- ------------ -----------------------------------------------------
  Guo et al[@b27-ott-8-313]            Multicenter, open-label\                                                                64                 Clear cell (100)        Sunitinib (33)\                    123 days                                 15 (23)                                                          0                        3 (4.7)   39 (60.9)    6.9 months
                                       Phase Ib study                                                                                                                     Sorafenib (50)\                                                                                                                                                                              
                                                                                                                                                                          Axitinib (6)\                                                                                                                                                                                
                                                                                                                                                                          Pazopanib (11)                                                                                                                                                                               

  Huang et al[@b30-ott-8-313]          Retrospective study                                                                     24                 Clear cell (83.3)\      Sunitinib only (10)\               169 days                                 --                                                               0                        0         15 (62.5)    7.1 months
                                                                                                                                                  Non-clear cell (16.7)   Sorafenib only (13) or both (1)                                                                                                                                                              

  Kato et al[@b31-ott-8-313]           Retrospective study                                                                     19                 Clear cell (78.9)\      Sunitinib only (11)\               --                                       2 (10.5)                                                         1 (5.3)                  0         15 (78.9)    8.4 months
                                                                                                                                                  Non-clear cell (21.1)   Sorafenib only (3)\                                                                                                                                                                          
                                                                                                                                                                          Sunitinib + sorafenib (3)\                                                                                                                                                                   
                                                                                                                                                                          Axitinib + sunitinib (1)\                                                                                                                                                                    
                                                                                                                                                                          Pazopanib + sunitinib (1)                                                                                                                                                                    

  Park et al[@b32-ott-8-313]           Retrospective study                                                                     100                Clear cell (86)\        Sunitinib only (73)\               120 days                                 12 (12)                                                          0                        3 (3)     69 (69)      4.2 months
                                                                                                                                                  Non-clear cell (14)     Sorafenib only (17)\                                                                                                                                                                         
                                                                                                                                                                          Pazopanib (10)                                                                                                                                                                               

  RECORD-1[@b29-ott-8-313] (updated)   Multicenter, randomized, double-blind, placebo-controlled, crossover, Phase III trial   277 (everolimus)   Clear cell (100)        Sunitinib only (124)\              141 days                                 54 (13)                                                          0                        5 (1.8)   185 (66.8)   4.9 months[c](#tfn3-ott-8-313){ref-type="table-fn"}
                                                                                                                                                                          Sorafenib only (81) or both (72)                                                                                                                                                             

                                                                                                                               139 (placebo)      Clear cell (100)        Sunitinib only (60)\               60 days                                  --                                                               0                        0         45 (32.4)    1.9 months
                                                                                                                                                                          Sorafenib only (43) or both (36)                                                                                                                                                             

  RECORD-1[@b28-ott-8-313]             Multicenter, randomized, double-blind, placebo-controlled, Phase III trial              272 (everolimus)   Clear cell (100)        Sunitinib only (124)\              95 days                                  10 (3.7)                                                         0                        3 (1)     171 (63)     4.0 months[c](#tfn3-ott-8-313){ref-type="table-fn"}
                                                                                                                                                                          Sorafenib only (77) or both (71)                                                                                                                                                             

                                                                                                                               138 (placebo)      Clear cell (100)        Sunitinib only (60)\               57 days                                  --                                                               0                        0         44 (32)      1.9 months
                                                                                                                                                                          Sorafenib only (42) or both (36)                                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Dose of everolimus used in all the studies was 10 mg/day

refers to discontinuation presumed to be related to everolimus treatment

*P*\<0.05, everolimus group versus placebo group.

**Abbreviations:** CR, complete response; PR, partial response; RECORD-1, renal cell cancer treatment with oral RAD001 given daily; SD, stable disease; PFS, progression-free survival.

###### 

Adverse effects of everolimus in the treatment of advanced renal cell carcinoma in Chinese patients, as referenced against the effects in Western patients

  Study                                                                All grades   Grades 3/4                                                                                                                                          
  -------------------------------------------------------------------- ------------ ------------------------------------------------ ------------------------------------------------ --------------------------- -------- ------ ----- ------
  Guo et al[@b27-ott-8-313]                                            Anemia       64                                               92                                               91                          Anemia   20     13    \<10
  Hypertriglyceridemia                                                 55           73                                               71                                               Hyperglycemia               13       \<16   12    
  Mouth ulceration                                                     53           44[a](#tfn5-ott-8-313){ref-type="table-fn"}      40[a](#tfn5-ott-8-313){ref-type="table-fn"}      Increased GGT               11       --     --    
  Hyperglycemia                                                        52           57                                               50                                               Hyponatremia                8        --     --    
  Hypercholesterolemia                                                 50           77                                               76                                               Dyspnea                     8        24     7     
  Pyrexia                                                              41           20                                               --                                               Hypertriglyceridemia        6        \<1    \<1   
  Increased lactate dehydrogenase                                      38           --                                               --                                               Lymphopenia                 6        18     0     
  Fatigue                                                              31           31                                               20                                               Noninfectious pneumonitis   6        4      3     
  Increased GGT                                                        31           --                                               --                                                                                                 
  Rash                                                                 31           29                                               25                                                                                                 
  Noninfectious pneumonitis[b](#tfn6-ott-8-313){ref-type="table-fn"}   31           14[b](#tfn6-ott-8-313){ref-type="table-fn"}      8[b](#tfn6-ott-8-313){ref-type="table-fn"}                                                         
  Huang et al[@b30-ott-8-313]                                          Anemia       70.8                                             92                                               91                          Anemia   25.0   13    \<10
  Hypercholesterolemia                                                 66.7         77                                               76                                               Hyperglycemia               16.7     \<16   12    
  Hypertriglyceridemia                                                 65.0         73                                               71                                               Mucositis                   8.3      1      1     
  Mucositis                                                            54.2         19                                               14                                               Pneumonitis                 8.3      4      3     
  Hyperglycemia                                                        50.0         57                                               50                                               Raised ALP                  8.3      --     \<1   
  Rash                                                                 45.8         29                                               25                                                                                                 
  Raised ALP                                                           25.0         --                                               37                                                                                                 
  Thrombocytopenia                                                     20.8         --                                               20                                                                                                 
  Raised AST/ALT                                                       20.5         25/21[c](#tfn7-ott-8-313){ref-type="table-fn"}   21/18[c](#tfn7-ott-8-313){ref-type="table-fn"}                                                     
  Pneumonitis                                                          16.4         14                                               8                                                                                                  

**Notes:**

References analyzed stomatitis which includes aphthous stomatitis, mouth ulceration, and stomatitis

noninfectious pneumonitis in the study by Guo et al includes interstitial lung disease, pneumonitis, and pulmonary fibrosis. References analyzed pneumonitis which includes interstitial lung disease, lung infiltration, pneumonitis, pulmonary alveolar hemorrhage, alveolitis, and pulmonary toxicity.

Incidence of AST and ALT was listed according to the reference, respectively.

**Abbreviations:** GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; RECORD-1, renal cell cancer treatment with oral RAD001 given daily.

###### 

Agents approved for targeted treatment of advanced renal cell carcinoma in Mainland China

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Targeting agents   Date admitted in Mainland China   Recommendation therapy   Efficacy in Chinese patients                        Common adverse effects
  ------------------ --------------------------------- ------------------------ --------------------------------------------------- ---------------------------------------------------------------------------------
  Sorafenib          November 2006                     First-line               More effective in Chinese than Western patients\    Hand-foot syndrome, diarrhea, fatigue, loss of appetite, alopecia
                                                                                Well tolerated\                                     
                                                                                Dose escalation in certain patients                 

  Sunitinib          May 2008                          First-line               Similar effective with sorafenib\                   Thrombocytopenia, hypothyroidism, neutropenia, hand-foot syndrome, hypertension
                                                                                Higher toxicity in Chinese than Western patients\   
                                                                                Dose reduction required in certain patients         

  Everolimus         January 2013                      After TKI failure        More effective in Chinese than Western patients\    Mouth ulceration, pyrexia, rash, noninfectious pneumonitis, anemia
                                                                                Rarely yields complete response\                    
                                                                                Well tolerated\                                     
                                                                                Dose reduction required in certain patients         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** TKI, tyrosine kinase inhibitor.

[^1]: \*These authors contributed equally to this work
